← Human Trials & Peer-Reviewed Studies
Resistance Training Performed With Single and Multiple Sets Induces Similar Improvements in Muscular Strength, Muscle Mass, Muscle Quality, and IGF-1 in Older Women: A Randomized Controlled Trial
Plain-language guide to PMID 30272625 (2020): single-blind randomized controlled trial study of IGF-1 LR3.
Key Facts
- PMID
- 30272625
- Journal
- Journal of strength and conditioning research
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Cunha PM et al. (9 authors)
- DOI
- 10.1519/JSC.0000000000002847
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at IGF-1 LR3.
J Strength Cond Res 34(4): 1008-1016, 2020-The purpose of this study was to compare the effects between single set vs. multiple sets of resistance training (RT) on measures of muscular strength, muscle mass, muscle quality (MQ), and insulin-like growth factor 1 (IGF-1) in untrained healthy older women.
Why It Was Studied
Cunha PM, Nunes JP, Tomeleri CM, Nascimento MA, Schoenfeld BJ, Antunes M, Gobbo LA, Teixeira D, and Cyrino ES.
Sixty-two older women were randomly assigned to 1 of the 3 groups: single-set RT (SS, n = 21), multiple-sets RT (MS, n = 20), or nontraining control (CG, n = 21).
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, women only.
How the Study Was Run
The researchers set it up as a randomized and single-blind study.
Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.
Only one side, usually the participants, was kept unaware of whether IGF-1 LR3 was given.
A time span of 12 weeks appears in the methods.
What Was Measured
Topics PubMed links to this paper include Anthropometry, Insulin-Like Growth Factor I, Muscle Strength, Muscle, Skeletal and Resistance Training.
What This Means in Plain Language
The paper is a randomized and single-blind study of IGF-1 LR3 over 12 weeks.
The publication is from 2020 (Journal of strength and conditioning research), a journal based in United States.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.